BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29942002)

  • 21. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.
    Giebel S; Labopin M; Socié G; Beauvais D; Klein S; Wagner-Drouet EM; Blaise D; Nguyen-Quoc S; Bourhis JH; Thiebaut A; Labussière-Wallet H; Charbonnier A; Berceanu A; Diez-Martin JL; Fegueux N; Esteve J; Nagler A; Mohty M
    Bone Marrow Transplant; 2021 May; 56(5):1047-1055. PubMed ID: 33235351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?
    Palmi C; Valsecchi MG; Longinotti G; Silvestri D; Carrino V; Conter V; Basso G; Biondi A; Kronnie GT; Cazzaniga G
    Haematologica; 2013 Aug; 98(8):1226-31. PubMed ID: 23585525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
    Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
    Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
    van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
    Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.
    Vitanza NA; Zaky W; Blum R; Meyer JA; Wang J; Bhatla T; Morrison DJ; Raetz EA; Carroll WL
    Pediatr Blood Cancer; 2014 Oct; 61(10):1779-85. PubMed ID: 24976218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
    Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
    J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical and laboratorial analysis for 15 adult cases of mixed phenotypic acute leukemia with Ph chromosome and/or positive BCR-ABL].
    Yan LZ; Chen SN; Ping NN; Wang QR; Liu H; Ding ZX; Zhu MQ; Liang JY; Liu DD; Cen JN; Pan JL; Qiu HY; Sun AN; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1116-20. PubMed ID: 24156417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis.
    Huang Z; Jia Y; Ruan G; Zuo Y; Wu J; Lu A; Xue Y; Cheng Y; Zhang L
    Pediatr Hematol Oncol; 2022 Apr; 39(3):243-253. PubMed ID: 34582325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.
    Clappier E; Grardel N; Bakkus M; Rapion J; De Moerloose B; Kastner P; Caye A; Vivent J; Costa V; Ferster A; Lutz P; Mazingue F; Millot F; Plantaz D; Plat G; Plouvier E; Poirée M; Sirvent N; Uyttebroeck A; Yakouben K; Girard S; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Cavé H;
    Leukemia; 2015 Nov; 29(11):2154-61. PubMed ID: 26050650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
    Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
    Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan.
    Yang YL; Hung CC; Chen JS; Lin KH; Jou ST; Hsiao CC; Sheen JM; Cheng CN; Wu KH; Lin SR; Yu SL; Chen HY; Lu MY; Wang SC; Chang HH; Lin SW; Su YN; Lin DT
    Cancer Sci; 2011 Oct; 102(10):1874-81. PubMed ID: 21740479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.
    Cazzaniga G; van Delft FW; Lo Nigro L; Ford AM; Score J; Iacobucci I; Mirabile E; Taj M; Colman SM; Biondi A; Greaves M
    Blood; 2011 Nov; 118(20):5559-64. PubMed ID: 21960589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.
    Ribera J; Morgades M; Zamora L; Montesinos P; Gómez-Seguí I; Pratcorona M; Sarrà J; Guàrdia R; Nomdedeu J; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; González-Campos J; Barba P; Escoda L; Genescà E; Solé F; Millá F; Feliu E; Ribera JM;
    Cancer; 2015 Nov; 121(21):3809-17. PubMed ID: 26194343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011.
    Olsson L; Castor A; Behrendtz M; Biloglav A; Forestier E; Paulsson K; Johansson B
    Leukemia; 2014 Feb; 28(2):302-10. PubMed ID: 23823658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined analysis of
    Cui L; Gao C; Wang CJ; Zhao XX; Li WJ; Li ZG; Zheng HY; Wang TY; Zhang RD
    Leuk Lymphoma; 2021 Feb; 62(2):410-418. PubMed ID: 33054468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
    Mullighan CG; Su X; Zhang J; Radtke I; Phillips LA; Miller CB; Ma J; Liu W; Cheng C; Schulman BA; Harvey RC; Chen IM; Clifford RJ; Carroll WL; Reaman G; Bowman WP; Devidas M; Gerhard DS; Yang W; Relling MV; Shurtleff SA; Campana D; Borowitz MJ; Pui CH; Smith M; Hunger SP; Willman CL; Downing JR;
    N Engl J Med; 2009 Jan; 360(5):470-80. PubMed ID: 19129520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways.
    Moreno Lorenzana D; Juárez Velázquez MDR; Reyes León A; Martínez Anaya D; Hernández Monterde A; Salas Labadía C; Navarrete Meneses MDP; Zapata Tarrés M; Juárez Villegas L; Jarquín Ramírez B; Cárdenas Cardós R; Herrera Almanza M; Paredes Aguilera R; Pérez Vera P
    J Pathol Clin Res; 2021 Jul; 7(4):410-421. PubMed ID: 33890726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.
    Huang YJ; Liu HC; Jaing TH; Wu KH; Wang SC; Yen HJ; Hsiao CC; Chen SH; Lin PC; Yeh TC; Sheen JM; Chen YC; Chang TK; Huang FL; Chao YH; Hou JY; Yang CP; Lin TH; Shih LY
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28899. PubMed ID: 33522704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.